Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Volenrelaxin?
Volenrelaxin is a protein commercialized by Eli Lilly and Co, with a leading Phase II program in Diastolic Heart Failure...